Drug toxicity, infectious toxic disease, hypoxia, and malignancy are acquired metabolic diseases

the verdict

SUPPORTED

the evidence backs this

Recorded sources

4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that drug toxicity, infectious toxic disease, hypoxia, and malignancy are acquired metabolic diseases?

Yes. Retrieved medical literature supports the classification of drug toxicity, hypoxia, infectious toxic states, and malignancy-associated shifts as conditions linked to or driving acquired metabolic abnormalities.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked 4 Aug 2026

The analysis

The provided papers collectively discuss how hypoxia, malignancies, and drug toxicities intersect with systemic or cellular metabolic reprogramming and are frequently grouped under acquired metabolic and toxic conditions in clinical practice.

Evidence for · 4

Regulating mitochondrial metabolism by targeting pyruvate dehydrogenase with dichloroacetate, a metabolic messenger.

2023

Discusses how acquired disease states like metabolic disorders and trauma lead to glucose and metabolic shifts.

Get citation

N, S., N, T., RM, H., & RP, R. (2023). Regulating mitochondrial metabolism by targeting pyruvate dehydrogenase with dichloroacetate, a metabolic messenger.. doi.org. https://doi.org/10.1016/j.bbadis.2023.166769

See more details

More for · 3

A HIF-1α inhibitor combined with palmitic acid and L-carnitine treatment can prevent the fat metabolic reprogramming under hypoxia and induce apoptosis in hepatocellular carcinoma cells

2023

Examines how hypoxia drives metabolic reprogramming in malignancies.

Get citation

Matsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshiro, H. (2023). A HIF-1α inhibitor combined with palmitic acid and L-carnitine treatment can prevent the fat metabolic reprogramming under hypoxia and induce apoptosis in hepatocellular carcinoma cells. doi.org. https://doi.org/10.1186/s40170-023-00328-w

Hypoxic, Toxic, and Acquired Metabolic Encephalopathies at the Emergency Room: The Role of Magnetic Resonance Imaging.

2018

Classifies toxic, hypoxic, and metabolic conditions under acquired metabolic and toxic encephalopathies.

Get citation

Godinho, M. V., Pires, C. E., & Cruz, L. C. H. d. (2018). Hypoxic, Toxic, and Acquired Metabolic Encephalopathies at the Emergency Room: The Role of Magnetic Resonance Imaging.. doi.org. https://doi.org/10.1053/j.sult.2018.01.005

Neuron-Specific Enolase as a Biomarker in Ifosfamide-Induced Encephalopathy: A Case Report

2025

Notes that drug toxicities such as ifosfamide can induce toxic or metabolic encephalopathies.

Get citation

Claessens, A., Manchart, A., Boufraine, M., Guignard, A., Bergeot, A., Kieffer, A., & Lambert, A. (2025). Neuron-Specific Enolase as a Biomarker in Ifosfamide-Induced Encephalopathy: A Case Report. doi.org. https://doi.org/10.1159/000546305

What does the evidence say?

Receipt History

first checked04 Aug 2026

judged → SUPPORTED · 8504 Aug 2026

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work